Daxor Announces New Clinical Studies Validate BVA Technology In High-Acuity Heart Failure Populations To Enhance Care At HFSA 2026 Annual Scientific Meeting

Daxor Corporation (NASDAQ: DXR) announced strong clinician interest and validation of its blood volume analysis (BVA™) technology at the HFSA 2026 Annual Scientific Meeting. New clinical studies demonstrated that BVA significantly improves diagnostic precision in high-acuity heart failure patients, revealing issues often missed by standard examinations. One study showed that BVA could optimize medical therapy in severe heart failure patients, leading to a statistically significant improvement in patient diuresis (p = 0.02). Another study highlighted BVA's ability to diagnose Plasma Volume Reserve depletion, enhancing clinical decision-making and treatment outcomes.